Cargando…

Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis

The MRZ reaction (MRZR) comprises the three antibody indices (AIs) against measles, rubella, and varicella zoster virus, reflecting an intrathecal polyspecific B cell response highly specific for multiple sclerosis (MS). Thus, MRZR can be used to confirm a diagnosis of primary progressive MS (PPMS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Robinson, Tilman, Abdelhak, Ahmed, Bose, Tanima, Meinl, Edgar, Otto, Markus, Zettl, Uwe K., Dersch, Rick, Tumani, Hayrettin, Rauer, Sebastian, Huss, André
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761295/
https://www.ncbi.nlm.nih.gov/pubmed/33255854
http://dx.doi.org/10.3390/cells9122543
_version_ 1783627535080226816
author Robinson, Tilman
Abdelhak, Ahmed
Bose, Tanima
Meinl, Edgar
Otto, Markus
Zettl, Uwe K.
Dersch, Rick
Tumani, Hayrettin
Rauer, Sebastian
Huss, André
author_facet Robinson, Tilman
Abdelhak, Ahmed
Bose, Tanima
Meinl, Edgar
Otto, Markus
Zettl, Uwe K.
Dersch, Rick
Tumani, Hayrettin
Rauer, Sebastian
Huss, André
author_sort Robinson, Tilman
collection PubMed
description The MRZ reaction (MRZR) comprises the three antibody indices (AIs) against measles, rubella, and varicella zoster virus, reflecting an intrathecal polyspecific B cell response highly specific for multiple sclerosis (MS). Thus, MRZR can be used to confirm a diagnosis of primary progressive MS (PPMS) but its pathophysiological and wider clinical relevance is unclear. This study aimed to investigate whether PPMS patients with a positive MRZR (MRZR+) differ from those with a negative MRZR (MRZR-) according to cerebrospinal fluid (CSF) biomarkers of B cell activity, neuroaxonal damage or glial activity, and clinical features. (1) Methods: In a multicenter PPMS cohort (n = 81) with known MRZR status, we measured B cell-activating factor (BAFF), chemokine CXC ligand 13 (CXCL-13), soluble B cell maturation antigen (sBCMA), soluble transmembrane activator and CAML interactor (sTACI), and chitinase-3-like protein 1 (CHI3L1) in the CSF with enzyme-linked immunosorbent assays (ELISAs). Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) were detected in serum and CSF using single molecule array (SIMOA) technology. (2) Results: MRZR+ patients (45.7% of all PPMS patients) revealed higher levels of NfL in CSF compared to MRZR- patients (54.3%). There were positive correlations between each of sBCMA, sTACI, and intrathecal immunoglobin G (IgG) synthesis. Additionally, NfL concentrations in serum positively correlated with those in CSF and those of GFAP in serum. However, MRZR+ and MRZR- patients did not differ concerning clinical features (e.g., age, disease duration, Expanded Disability Status Scale (EDSS) at diagnosis and follow-up); CSF routine parameters; CSF concentrations of BAFF, CXCL-13, sBCMA, sTACI, CHI3L1, and GFAP; or serum concentrations of GFAP and NfL. (3) Conclusions: In PPMS patients, MRZR positivity might indicate a more pronounced axonal damage. Higher levels of the soluble B cell receptors BCMA and transmembrane activator and CAML interactor (TACI) in CSF are associated with a stronger intrathecal IgG synthesis in PPMS.
format Online
Article
Text
id pubmed-7761295
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77612952020-12-26 Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis Robinson, Tilman Abdelhak, Ahmed Bose, Tanima Meinl, Edgar Otto, Markus Zettl, Uwe K. Dersch, Rick Tumani, Hayrettin Rauer, Sebastian Huss, André Cells Article The MRZ reaction (MRZR) comprises the three antibody indices (AIs) against measles, rubella, and varicella zoster virus, reflecting an intrathecal polyspecific B cell response highly specific for multiple sclerosis (MS). Thus, MRZR can be used to confirm a diagnosis of primary progressive MS (PPMS) but its pathophysiological and wider clinical relevance is unclear. This study aimed to investigate whether PPMS patients with a positive MRZR (MRZR+) differ from those with a negative MRZR (MRZR-) according to cerebrospinal fluid (CSF) biomarkers of B cell activity, neuroaxonal damage or glial activity, and clinical features. (1) Methods: In a multicenter PPMS cohort (n = 81) with known MRZR status, we measured B cell-activating factor (BAFF), chemokine CXC ligand 13 (CXCL-13), soluble B cell maturation antigen (sBCMA), soluble transmembrane activator and CAML interactor (sTACI), and chitinase-3-like protein 1 (CHI3L1) in the CSF with enzyme-linked immunosorbent assays (ELISAs). Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) were detected in serum and CSF using single molecule array (SIMOA) technology. (2) Results: MRZR+ patients (45.7% of all PPMS patients) revealed higher levels of NfL in CSF compared to MRZR- patients (54.3%). There were positive correlations between each of sBCMA, sTACI, and intrathecal immunoglobin G (IgG) synthesis. Additionally, NfL concentrations in serum positively correlated with those in CSF and those of GFAP in serum. However, MRZR+ and MRZR- patients did not differ concerning clinical features (e.g., age, disease duration, Expanded Disability Status Scale (EDSS) at diagnosis and follow-up); CSF routine parameters; CSF concentrations of BAFF, CXCL-13, sBCMA, sTACI, CHI3L1, and GFAP; or serum concentrations of GFAP and NfL. (3) Conclusions: In PPMS patients, MRZR positivity might indicate a more pronounced axonal damage. Higher levels of the soluble B cell receptors BCMA and transmembrane activator and CAML interactor (TACI) in CSF are associated with a stronger intrathecal IgG synthesis in PPMS. MDPI 2020-11-25 /pmc/articles/PMC7761295/ /pubmed/33255854 http://dx.doi.org/10.3390/cells9122543 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Robinson, Tilman
Abdelhak, Ahmed
Bose, Tanima
Meinl, Edgar
Otto, Markus
Zettl, Uwe K.
Dersch, Rick
Tumani, Hayrettin
Rauer, Sebastian
Huss, André
Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis
title Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis
title_full Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis
title_fullStr Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis
title_full_unstemmed Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis
title_short Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis
title_sort cerebrospinal fluid biomarkers in relation to mrz reaction status in primary progressive multiple sclerosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761295/
https://www.ncbi.nlm.nih.gov/pubmed/33255854
http://dx.doi.org/10.3390/cells9122543
work_keys_str_mv AT robinsontilman cerebrospinalfluidbiomarkersinrelationtomrzreactionstatusinprimaryprogressivemultiplesclerosis
AT abdelhakahmed cerebrospinalfluidbiomarkersinrelationtomrzreactionstatusinprimaryprogressivemultiplesclerosis
AT bosetanima cerebrospinalfluidbiomarkersinrelationtomrzreactionstatusinprimaryprogressivemultiplesclerosis
AT meinledgar cerebrospinalfluidbiomarkersinrelationtomrzreactionstatusinprimaryprogressivemultiplesclerosis
AT ottomarkus cerebrospinalfluidbiomarkersinrelationtomrzreactionstatusinprimaryprogressivemultiplesclerosis
AT zettluwek cerebrospinalfluidbiomarkersinrelationtomrzreactionstatusinprimaryprogressivemultiplesclerosis
AT derschrick cerebrospinalfluidbiomarkersinrelationtomrzreactionstatusinprimaryprogressivemultiplesclerosis
AT tumanihayrettin cerebrospinalfluidbiomarkersinrelationtomrzreactionstatusinprimaryprogressivemultiplesclerosis
AT rauersebastian cerebrospinalfluidbiomarkersinrelationtomrzreactionstatusinprimaryprogressivemultiplesclerosis
AT hussandre cerebrospinalfluidbiomarkersinrelationtomrzreactionstatusinprimaryprogressivemultiplesclerosis